Eli Lilly (LLY) Is Suing Six Companies Over an Unapproved Drug—Leaving Novo Nordisk (NVO) Clear in the GLP-1 Wars

On August 12, 2026, Eli Lilly filed lawsuits against six US companies accused of selling unauthorized versions of their experimental weight-loss drug retatrutide. The drug is still in Phase 3 trials and not yet approved by any regulatory body. This aggressive legal action raises questions about the motivation behind Lilly's efforts to control a black market for a drug that has not yet been launched.

The lawsuits target various businesses including compounding pharmacies, medical spas, and online sellers. Lilly has referred over 200 individuals and entities to the FDA, Justice Department, state attorneys general, and law enforcement. US Customs and Border Protection intercepted more than 690 shipments of illicit GLP-1 drugs in fiscal 2025, with the number increasing to over 1,400 seizures in July 2026 alone.

Retatrutide has helped obese patients with type 2 diabetes lose nearly 13% of their body weight after 80 weeks in trials. Lilly plans to seek US approval for retatrutide as a biologic in the first quarter of 2027. While Lilly is managing a burgeoning black market, Novo Nordisk has largely avoided similar enforcement battles with its approved Wegovy product.

This legal campaign by Lilly precedes any potential revenue from the drug. Novo Nordisk remains in fewer hedge fund portfolios compared to Eli Lilly.